P8

General Information


DRACP ID  DRACP01093

Peptide Name   P8

Sequence  KWKKFLKIGIGKFLHLAKKF

Sequence Length  20

UniProt ID  Not available

PubChem CID  Not available

Origin  Ceropin A-Magainin 2

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
NCI-H128 Lung small cell carcinoma; Small cell lung cancer Carcinoma IC50=2.3 µM MTT assay 72 h 1
NCI-H146 Lung small cell carcinoma; Small cell lung cancer Carcinoma IC50=1.8 µM MTT assay 72 h 1
NCI-H69 Lung small cell carcinoma; Small cell lung cancer Carcinoma IC50=2.6 µM MTT assay 72 h 1

Hemolytic Activity  Human red blood cells: hemolysis 2.4%(50 μg/mL); hemolysis 13.7%(100 μg/mL)

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01093

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C123H196N30O21

Absent amino acids  CDEMNPQRSTVY

Common amino acids  K

Mass  277019

Pl  11.58

Basic residues  8

Acidic residues  0

Hydrophobic residues  10

Net charge  8

Boman Index  -395

Hydrophobicity  -8

Aliphatic Index  102.5

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  5500

Absorbance 280nm  289.47

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 9352466

Title  Structure-antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 21 and cecropin A-melittin hybrid peptides

Doi 10.1111/j.1399-3011.1997.tb01469.x

Year  1997

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.